Zealand Pharma

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

The drug, called survodutide and developed by Boehringer Ingelheim and Zealand Pharma, is also in Phase 3 trials for obesity.

Boehringer Ingelheim has linked its Zealand Pharma-partnered candidate to improvements in disease activity and liver scarring in a phase 2 trial.

Today's biotech news updates include the return of the MASH goldrush, next year's flu shot, and Alnylam's recovery.

Essential digital access to quality FT journalism on any device. All discounts based on monthly full price over contract term. Cancel subscription renewal ...

Zealand Pharma (ZEAL.CO) stock skyrockets on positive results from a liver disease treatment trial. JPMorgan analysts upgrade retailer The Gap (GPS) to ...

Discover how Altimmune's stock witnessed a significant surge after Zealand Pharma's positive Phase 2 clinical trial results for survodutide, ...

By Ludwig Burger FRANKFURT (Reuters) - Zealand Pharma shares jumped 20% after an experimental obesity treatment it is developing with Boehringer Ingelheim ...

The study result is the latest evidence new weight loss drugs that affect insulin production could help people with a common liver disease, too.

Shares of Danish biotechnology research business, Zealand Pharma A/S, skyrocketed 30% on Monday after sharing that its trial liver disease treatment was ...

On Monday, Zealand Pharma shares were the biggest risers on the STOXX 600 index, following positive results from a treatment developed with Boehringer ...

Danish biotechnology research company Zealand Pharma A/S (CSE:ZELA) (ZLDPF) saw its shares soar more than 35% in Copenhagen on Monday after following ...

The competition against Novo Nordisk and Eli Lilly is heating up as several companies look to get in on on the weight loss drug gold rush.

Promising mid-stage trial results for an experimental weight-loss drug by Zealand Pharma and Boehringer Ingelheim could mark a breakthrough in treating ...

Shares in Zealand Pharma jumped 22% on Monday after an experimental drug it is developing with Boehringer Ingelheim yielded "groundbreaking" mid-stage trial ...

Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity...

We look forward to important clinical results for petrelintide and dapiglutide in obesity that we believe will support advancing both compounds into subsequent ...

Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes ...

Copenhagen, Denmark, February 27, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

Weight-loss drug Wegovy may soon have a new challenger developed by Danish Zealand Pharma and German Boehringer Ingelheim. Carsten Snejbjerg—Bloomberg/Getty ...

Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes ...